Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hebert

Showing results (421-430 of 460) with videos related to

Pageof 46
Sort By:
Journal of Drugs in Dermatology : JDD|February 2, 2024
INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES StudyHilary E Baldwin, Emmy Graber, Julie C Harper, et al.
Pediatric Dermatology|August 27, 2025
Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 YearsAdelaide A Hebert, Shireen V Guide, Vlada Groysman, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjectsRobert Matheson, Steven Kempers, Debra Breneman, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|March 3, 2021
Telehealth's New Horizon: Providing Smart Hospital-Level Care in the HomeJoseph M Rosen, Lisa V Adams, James Geiling, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
The Journal of Clinical Investigation|July 20, 1999
Safety and antitumor activity of recombinant soluble Apo2 ligandA Ashkenazi, R C Pai, S Fong, et al.
Molecular Imaging and Biology|November 29, 2022
Current and Future Applications of Fluorescence Guidance in Orthopaedic SurgerySamuel S Streeter, Kendra A Hebert, Logan M Bateman, et al.
Pageof 46

Showing results (421-430 of 460) with videos related to

Sort By:
Pageof 46
Journal of Drugs in Dermatology : JDD|February 2, 2024
INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES StudyHilary E Baldwin, Emmy Graber, Julie C Harper, et al.
Pediatric Dermatology|August 27, 2025
Early Evidence of Safety, Clinical Benefit, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Mild or Moderate Plaque Psoriasis in Children Aged 2-11 YearsAdelaide A Hebert, Shireen V Guide, Vlada Groysman, et al.
Journal of Drugs in Dermatology : JDD|April 3, 2008
Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjectsRobert Matheson, Steven Kempers, Debra Breneman, et al.
Telemedicine Journal and E-Health : the Official Journal of the American Telemedicine Association|March 3, 2021
Telehealth's New Horizon: Providing Smart Hospital-Level Care in the HomeJoseph M Rosen, Lisa V Adams, James Geiling, et al.
Pediatric Dermatology|March 8, 2026
Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5 Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE)Lawrence F Eichenfield, Mercedes E Gonzalez, Mark Boguniewicz, et al.
Journal of Drugs in Dermatology : JDD|June 4, 2025
Rapid Onset of Itch Relief With Tapinarof in Two Phase 3 Trials in Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Robert Bissonnette, et al.
Journal of the American Academy of Dermatology|May 18, 2025
Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitisRobert Bissonnette, Linda Stein Gold, Leon Kircik, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
The Journal of Clinical Investigation|July 20, 1999
Safety and antitumor activity of recombinant soluble Apo2 ligandA Ashkenazi, R C Pai, S Fong, et al.
Molecular Imaging and Biology|November 29, 2022
Current and Future Applications of Fluorescence Guidance in Orthopaedic SurgerySamuel S Streeter, Kendra A Hebert, Logan M Bateman, et al.
Pageof 46